Shares in Zeneca sent 35p higher on Roche bid rumours
Saturday 12 April 1997
The bid rumour, the latest in a long series, emerged in a report in a Swiss newspaper which suggested that an offer worth pounds 21 to pounds 22 a share would be launched by Roche early next week. Cash, a weekly financial publication, claimed the two companies were in talks and the Basle-based Roche planned to sell off Zeneca's agrochemicals and specialty chemicals operations, keeping only the drugs business.
Neither company would comment yesterday. A representative for Roche said: "We've heard the rumours before and we didn't comment then and we are not commenting now."
The Swiss company has substantial cash resources and is thought to be interested in making acquisitions, but analysts played down the latest twist to what has become a long-running saga. James Dodwell, a pharmaceuticals watcher at Barclays de Zoete Wedd, said the two companies would fit together reasonably well. Roche had a lot of hospital products, while Zeneca's portfolio was strong in drugs targeted at GPs. Zeneca also had a strong franchise in cancer treatments, which Roche lacked, he suggested.
But he said: "Zeneca won't go freely. They want to remain independent and have said they are going to achieve 15 per cent per annum earnings growth for the next five years." Even for Roche, the possible $35bn price tag for the British group would be hard to digest, while the rating might be hard to justify.
The one piece of tangible good news yesterday for Zeneca, headed by chief executive Sir David Barnes, was that a US appeal court had upheld its patent rights over Nolvadex, still the most widely used treatment for breast cancer nearly quarter of a century after its launch. The appeal to the Federal court followed a challenge by Novopharm, a Canadian maker of generic drugs, which had been thrown out by a lower court in Maryland last April. Zeneca said the decision disposed of the proceedings instituted by Novopharm, which had wanted to produce a generic form of the drug.
The decision helps protect Zeneca's US patent until its expiry in 2002, although the company said it would continue patent infringement proceedings against two other companies, Mylan Pharmaceuticals and Pharmachemie, which have submitted applications for generic forms of the drug with America's Food and Drug Administration.
- 2 Question Time's 'passionate highlander' is the William Wallace of the Better Together campaign
- 3 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
- 5 The true Gaza back-story that the Israelis aren’t telling this week
Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Question Time's 'passionate highlander' is the William Wallace of the Better Together campaign
Israel-Gaza crisis: Eight killed in Gaza Strip cafe while watching World Cup semi-final
Supermoon 2014: When and why will the moon look bigger and brighter this summer?
Sustained immigration has not harmed Britons' employment, say government advisers
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
There’s a nasty smell in the political air – and it’s coming from the Tories
iJobs Money & Business
£50000 - £70000 per annum: Harrington Starr: Business Analyst Consultant (Fina...
£300 - £350 per day + competitive: Orgtel: My client, a leading bank, is curre...
£28000 - £32000 per annum + pension, 25 days holiday: Ashdown Group: A highly ...
Negotiable: Randstad Education Birmingham: Randstad Education are seeking a Fi...